Quidel Stock Price, News & Analysis

Quidel is hosting a free webinar on May 5 to help healthcare providers differentiate between Lyme disease, COVID-19, and the flu. With Lyme disease affecting up to 400,000 Americans annually, accurate diagnosis is crucial, especially during peak tick season. Dr. Sean McCloy will lead the session, discussing the similarities in symptoms and highlighting the Sofia® 2 Lyme FIA test, which provides results in 15 minutes. This test enhances timely treatment, allowing physicians to act quickly based on patient needs.

Quidel Corporation (NASDAQ: QDEL) will announce its fiscal Q1 2021 financial results on May 6, 2021, after market close. CEO Douglas Bryant and CFO Randy Steward will host a conference call at 5:00 PM ET to discuss the results, business developments, and address questions. The company emphasizes that the call may include material undisclosed information. A live webcast will be available on their website, with replays accessible for one year and telephone replays for 14 days starting after the call.

Quidel Corporation (NASDAQ: QDEL) has finalized a distribution agreement with McKesson Corporation to enhance access to its QuickVue® At-Home OTC COVID-19 Test. This partnership aims to expedite the rollout to various markets, including schools and businesses. McKesson will leverage its retail and e-commerce platforms to facilitate the product's distribution. The QuickVue Test, authorized by the FDA, provides results in under 10 minutes and boasts high accuracy, agreeing with PCR results 83.5% of the time. Shipping is set to commence soon.

Quidel Corporation (QDEL) announced preliminary results for Q1 2021, projecting revenues between $374 million and $376 million, marking a 114% increase from $174.7 million in Q1 2020. COVID-19 test revenues are expected to exceed $280 million, a significant rise from $1 million last year. Despite strong performance in SARS tests, influenza product sales dropped to $5 million from $79.6 million due to an uncharacteristically low respiratory season. Gross margins are estimated at 80%, with earnings growth exceeding 300%. Further details are anticipated in their earnings call on May 6, 2021.

Quidel Corporation has partnered with the Bay Area Lyme Foundation to raise public awareness about Lyme disease, which affects up to 400,000 Americans annually. The collaboration includes sponsoring a series of free speaker forums focused on Lyme disease research and prevention. The first forum will take place on May 19, addressing herbal treatments for tick-borne diseases. Additionally, Quidel will support BAL’s Emerging Leader Awards and the annual LymeAid Gala, aimed at promoting research innovation. Quidel's Sofia® 2 Lyme FIA test provides rapid, accurate results, significantly improving early diagnosis.

As Lyme disease season approaches, Quidel Corporation emphasizes the importance of awareness and testing. Up to 400,000 Americans are infected annually, with symptoms often mimicking COVID-19. Dr. Judi Tilghman advises outdoor enthusiasts to take precautionary measures against ticks and seek immediate testing if symptoms arise.

Quidel’s Sofia® 2 Lyme test offers rapid results, aiding timely diagnosis and treatment. The company's mission focuses on providing accessible, accurate health diagnostics, enhancing patient care across diverse health conditions.

Quidel Corporation (NASDAQ: QDEL) has received Emergency Use Authorization (EUA) from the FDA for its Sofia® SARS Antigen FIA. This test detects SARS-CoV-2 antigens from nasal swabs, allowing usage without a prescription for asymptomatic individuals under specific testing conditions. The test shows a strong correlation with PCR results (96.7% agreement for positives, 100% for negatives) within five days of symptom onset. While the company aims for broad application to enhance early detection, ongoing studies seek to confirm clinical performance among asymptomatic patients.

Quidel Corporation (NASDAQ: QDEL) has been named the Official Diagnostics Partner of the San Diego Padres, a Major League Baseball franchise. Quidel will supply its Sofia® 2 instruments and Sofia® SARS Antigen tests to support the Padres' medical staff and event personnel, enhancing safety measures at Petco Park. This partnership aims to ensure a safe experience for attendees during games, with rapid test results delivered in just 15 minutes. Quidel has been at the forefront of COVID-19 testing innovation, underscoring its commitment to public health in the San Diego community.

Quidel (NASDAQ: QDEL) announced a partnership with the CDC and NIH for the “Say Yes! COVID Test” initiative in Pitt County, NC, and Chattanooga, TN. The program aims to distribute two million free QuickVue® At-Home OTC COVID-19 Tests to approximately 160,000 residents. This innovative study assesses whether regular access to at-home antigen tests can effectively reduce virus transmission in vulnerable communities. The QuickVue test is user-friendly, delivering results in 10 minutes with high accuracy rates. This initiative seeks to provide foundational data to inform future pandemic responses.